HomeCompareADKCF vs ABBV

ADKCF vs ABBV: Dividend Comparison 2026

ADKCF yields 3.14% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $77.9K in total portfolio value
10 years
ADKCF
ADKCF
● Live price
3.14%
Share price
$22.50
Annual div
$0.71
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$384.18
Full ADKCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ADKCF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADKCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADKCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADKCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADKCF
Annual income on $10K today (after 15% tax)
$266.79/yr
After 10yr DRIP, annual income (after tax)
$326.55/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,729.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADKCF + ABBV for your $10,000?

ADKCF: 50%ABBV: 50%
100% ABBV50/50100% ADKCF
Portfolio after 10yr
$63.4K
Annual income
$12,577.97/yr
Blended yield
19.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ADKCF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADKCF buys
0
ABBV buys
0
No recent congressional trades found for ADKCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADKCFABBV
Forward yield3.14%3.06%
Annual dividend / share$0.71$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$24.5K$102.3K
Annual income after 10y$384.18$24,771.77
Total dividends collected$3.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ADKCF vs ABBV ($10,000, DRIP)

YearADKCF PortfolioADKCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,014$313.87$11,550$430.00$536.00ABBV
2$12,108$323.07$13,472$627.96$1.4KABBV
3$13,287$331.93$15,906$926.08$2.6KABBV
4$14,558$340.43$19,071$1,382.55$4.5KABBV
5$15,926$348.59$23,302$2,095.81$7.4KABBV
6$17,397$356.39$29,150$3,237.93$11.8KABBV
7$18,978$363.84$37,536$5,121.41$18.6KABBV
8$20,678$370.95$50,079$8,338.38$29.4KABBV
9$22,503$377.73$69,753$14,065.80$47.3KABBV
10$24,462$384.18$102,337$24,771.77$77.9KABBV

ADKCF vs ABBV: Complete Analysis 2026

ADKCFStock

Adeka Corporation engages in chemicals, food products, and life science businesses. The company offers polymer additives, such as antioxidants, UV absorbers/hindered amine light stabilizers, nucleating agents/clarifiers, metal deactivators/additives for filled polymers, flame retardants, epoxy type stabilizers/lubricants/processability improvers/water dispersion type stabilizers; plasticizers/PVC stabilizers; and light/thermal curing materials, initiators, polymerizable materials, resist materials, thermal paper materials, semiconductor materials, and circuit materials. Its chemical products also comprise functional polymers, including water borne, epoxy, low chlorine epoxy, and urethane resins; surface specialties, such as general-purpose and functional surfactants, functional cosmetic ingredients, lubricant additives, and base materials for lubricants; propylene glycol, peroxygen chemicals, metal soaps, and inorganic chemicals; and inducing joint fillers and sealing materials, as well as civil engineering and construction materials. The company offers its chemical products to electronics and IT, plastics and rubber, personal care, industrial, liquid crystal display, automotive, and building and construction industries, as well as paints, coatings, and adhesives industries. In addition, it provides food products, such as margarines, shortening products, oils and fats for chocolate, frying oil, whipping cream, concentrated milk type creams, fillings, frozen pie doughs, mayonnaise and dressing, functional foods, and others under the RISU BRAND name. Further, the company engages in various businesses, such as plant facility design; construction and construction management; and facility maintenance, logistics, warehousing, vehicles leasing, real estate, and insurance agency. The company was formerly known as Asahi Denka Co., Ltd. and changed its name to Adeka Corporation in May 2006. The company was incorporated in 1917 and is headquartered in Tokyo, Japan.

Full ADKCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ADKCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADKCF vs SCHDADKCF vs JEPIADKCF vs OADKCF vs KOADKCF vs MAINADKCF vs JNJADKCF vs MRKADKCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.